SG11201810853UA - Anti-tnfrsf25 antibodies - Google Patents
Anti-tnfrsf25 antibodiesInfo
- Publication number
- SG11201810853UA SG11201810853UA SG11201810853UA SG11201810853UA SG11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antibodies
- pct
- durham
- english
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
WO 17 / 2145 47 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIP0 I PCT omit VIII two Hol olommoomommom oimIE (10) International Publication Number WO 2017/214547 Al (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2017/036817 (22) International Filing Date: 09 June 2017 (09.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/348,009 09 June 2016 (09.06.2016) US (71) Applicant: PELICAN THERAPEUTICS, INC. [US/US]; 801 Capitola Drive, Bay 12, Durham, North Car- olina 27713 (US). (72) Inventors: SCHREIBER, Taylor H.; 3611 Rugby Rd, Durham, North Carolina 27707 (US). HUTCHINS, Jeff T.; 15823 S. 4210 Rd., Claremore, Oklahoma 74017 (US). (74) Agent: ALTIERI, Stephen, L.; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, N.W., Washington, DC 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-TNFRSF25 ANTIBODIES (57) : Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348009P | 2016-06-09 | 2016-06-09 | |
| PCT/US2017/036817 WO2017214547A1 (en) | 2016-06-09 | 2017-06-09 | Anti-tnfrsf25 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810853UA true SG11201810853UA (en) | 2019-01-30 |
Family
ID=59078259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810853UA SG11201810853UA (en) | 2016-06-09 | 2017-06-09 | Anti-tnfrsf25 antibodies |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10005843B2 (en) |
| EP (1) | EP3468998B1 (en) |
| JP (1) | JP6961625B2 (en) |
| KR (1) | KR102423942B1 (en) |
| CN (1) | CN109219620B (en) |
| AU (1) | AU2017278192A1 (en) |
| BR (1) | BR112018075222A2 (en) |
| CA (1) | CA3026652A1 (en) |
| DK (1) | DK3468998T3 (en) |
| IL (1) | IL263406B2 (en) |
| MX (1) | MX389320B (en) |
| RU (1) | RU2746314C2 (en) |
| SG (1) | SG11201810853UA (en) |
| WO (1) | WO2017214547A1 (en) |
| ZA (1) | ZA201808317B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017016681A2 (en) * | 2015-02-06 | 2018-04-10 | Heat Biologics Inc | vaccine and costimulatory molecules coexpression vector |
| TWI703158B (en) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | Antibodies that specifically bind to tl1a |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2021041672A1 (en) * | 2019-08-30 | 2021-03-04 | Pelican Therapeutics, Inc. | Methods of treating cancer using tnfrsf25 antibodies |
| EP4034563A4 (en) * | 2019-09-26 | 2023-11-08 | Pelican Therapeutics, Inc. | TNFRSF25-MEDIATED TREATMENTS OF IMMUNE DISEASES AND DISORDERS |
| WO2022212668A1 (en) * | 2021-03-31 | 2022-10-06 | Heat Biologics, Inc. | Methods and compositions related to tnfrsf25/dr3 agonists |
| CN116514983B (en) * | 2023-06-02 | 2025-05-23 | 安徽金百奥生物科技有限公司 | Nanometer antibody targeting DR3 extracellular domain and application thereof |
| GB202315963D0 (en) | 2023-10-18 | 2023-11-29 | Cancer Research Tech Ltd | Binding molecules |
| US12319742B1 (en) * | 2024-01-24 | 2025-06-03 | Shattuck Labs, Inc. | Antibodies that bind TNFRSF25 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU658396B2 (en) | 1991-03-06 | 1995-04-13 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric monoclonal antibodies |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
| GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| SG52215A1 (en) | 1992-02-19 | 1998-09-28 | Schering Corp | Cloning and expresssion of humanized monoclonal antibodies against human interleukin-4 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| CA2536086C (en) | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
| US7612179B2 (en) | 2003-11-28 | 2009-11-03 | Astrazeneca Ab | antibodies binding to a C-terminal fragment of apoliopoprotein E |
| US20070128184A1 (en) | 2005-08-30 | 2007-06-07 | Eckhard Podack | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins |
| LT2486941T (en) | 2006-10-02 | 2017-06-12 | E. R. Squibb & Sons, L.L.C. | Human antibodies that bind CXCR4 and uses thereof |
| FR2907341B1 (en) | 2006-10-18 | 2012-08-17 | Pf Medicament | USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER |
| WO2010033913A1 (en) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| SG10201502330TA (en) * | 2009-08-03 | 2015-05-28 | Univ Miami | Method for in vivo expansion of t regulatory cells |
| WO2011106707A2 (en) * | 2010-02-26 | 2011-09-01 | Human Genome Sciences, Inc. | Antibodies that specifically bind to dr3 |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| JP2013040160A (en) | 2011-07-01 | 2013-02-28 | Genentech Inc | Use of anti-cd83 agonist antibody for treating autoimmune disease |
| CA2897826C (en) | 2013-01-09 | 2022-09-27 | Taylor H. Schreiber | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
| RU2551235C2 (en) * | 2013-08-26 | 2015-05-20 | Илья Владимирович Духовлинов | Humanised monoclonal antibody specific to syndecan-1 |
| CN103592439B (en) * | 2013-09-03 | 2015-10-21 | 天津亿美诺生物科技有限公司 | Human urothelial carcinoma specific antibody and application thereof |
| WO2016081455A1 (en) * | 2014-11-17 | 2016-05-26 | Pelican Therapeutics, Inc. | Human tnfrsf25 antibody |
-
2017
- 2017-06-09 KR KR1020187035804A patent/KR102423942B1/en active Active
- 2017-06-09 US US15/618,993 patent/US10005843B2/en active Active
- 2017-06-09 WO PCT/US2017/036817 patent/WO2017214547A1/en unknown
- 2017-06-09 CA CA3026652A patent/CA3026652A1/en active Pending
- 2017-06-09 EP EP17731434.1A patent/EP3468998B1/en active Active
- 2017-06-09 RU RU2018143977A patent/RU2746314C2/en active
- 2017-06-09 DK DK17731434.1T patent/DK3468998T3/en active
- 2017-06-09 SG SG11201810853UA patent/SG11201810853UA/en unknown
- 2017-06-09 AU AU2017278192A patent/AU2017278192A1/en not_active Abandoned
- 2017-06-09 CN CN201780034593.5A patent/CN109219620B/en not_active Expired - Fee Related
- 2017-06-09 MX MX2018014716A patent/MX389320B/en unknown
- 2017-06-09 JP JP2018563618A patent/JP6961625B2/en not_active Expired - Fee Related
- 2017-06-09 BR BR112018075222-3A patent/BR112018075222A2/en not_active IP Right Cessation
- 2017-06-09 IL IL263406A patent/IL263406B2/en unknown
-
2018
- 2018-04-27 US US15/964,775 patent/US10683359B2/en not_active Expired - Fee Related
- 2018-12-10 ZA ZA2018/08317A patent/ZA201808317B/en unknown
-
2020
- 2020-05-14 US US16/874,290 patent/US20210017287A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL263406A (en) | 2018-12-31 |
| ZA201808317B (en) | 2019-08-28 |
| US20210017287A1 (en) | 2021-01-21 |
| US20170355773A1 (en) | 2017-12-14 |
| BR112018075222A2 (en) | 2019-03-19 |
| US10683359B2 (en) | 2020-06-16 |
| DK3468998T3 (en) | 2022-03-07 |
| RU2018143977A (en) | 2020-07-09 |
| IL263406B1 (en) | 2023-05-01 |
| AU2017278192A1 (en) | 2018-12-13 |
| IL263406B2 (en) | 2023-09-01 |
| US10005843B2 (en) | 2018-06-26 |
| US20180312599A1 (en) | 2018-11-01 |
| WO2017214547A1 (en) | 2017-12-14 |
| MX389320B (en) | 2025-03-20 |
| EP3468998B1 (en) | 2021-12-01 |
| RU2018143977A3 (en) | 2020-10-05 |
| CN109219620A (en) | 2019-01-15 |
| JP6961625B2 (en) | 2021-11-10 |
| RU2746314C2 (en) | 2021-04-12 |
| KR102423942B1 (en) | 2022-07-22 |
| CN109219620B (en) | 2023-01-31 |
| JP2019526528A (en) | 2019-09-19 |
| MX2018014716A (en) | 2019-03-11 |
| EP3468998A1 (en) | 2019-04-17 |
| KR20190015716A (en) | 2019-02-14 |
| CA3026652A1 (en) | 2017-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810853UA (en) | Anti-tnfrsf25 antibodies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808196UA (en) | Neoantigens and methods of their use | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201408261UA (en) | Syringe | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201803642WA (en) | Bacteria-based protein delivery |